RBC Capital keeps a Buy rating and $82 price target on Cytokinetics (CYTK), saying the firm remains bullish on the stock following the announcement that upon the completion of their mid-cycle review meeting with the FDA ahead of the September 26th PDUFA, the company does not expect an AdComm review and continues to expect a differentiated label and REMS program for aficamten vs. other approved CMIs, or cardiac myosin inhibitors, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics says FDA does not plan advisory committee meeting for aficamten NDA
- Cytokinetics Completes Midcycle Review with FDA for Aficamten
- Cytokinetics Positioned for Growth: Buy Rating Backed by Aficamten’s Market Potential and Upcoming PDUFA Date
- Cytokinetics assumed with an Overweight at Morgan Stanley
- Cytokinetics Positioned for Growth with Aficamten’s Imminent Launch and Strong Financials